Vol. 2 No. 7 (2022)
Reimbursement Recommendations

Normal Immunoglobulin (Human) 10% and Recombinant Human Hyaluronidase (HyQvia)

Published July 4, 2022

Key Messages

  • CADTH recommends that HyQvia should be reimbursed for the treatment of primary humoral immunodeficiency and secondary humoral immunodeficiency if certain conditions are met.
  • HyQvia should only be covered to treat adults with primary or secondary humoral immunodeficiency if it is covered in a similar way as other immunoglobulin replacement therapies (IgRTs) currently reimbursed for the treatment of these conditions.
  • HyQvia should only be reimbursed if prescribed by a specialist with appropriate knowledge and training in primary and secondary humoral immunodeficiency and if treatment with HyQvia does not cost more than the least costly IgRT currently reimbursed for this condition.